Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of February 2025. The report details significant corporate actions including the closing of a public offering, amendments to the Articles of Association, share capital increases, and the granting of new warrants to directors, management, and employees.
Key Financial Metrics and Capital Structure
The filing focuses on capitalization events rather than operational financial performance metrics such as revenue or cash flow.
- Public Offering: Closed on January 31, 2025, for 3,997,361 ADSs and warrants at a combined price of $2.71 per ADS.
- Share Capital Increase (Jan 31): Nominal DKK 49,967,012.50, resulting in a total nominal share capital of DKK 78,332,151.50 (199,868,050 shares issued).
- Share Capital Increase (Feb 5): Nominal DKK 625,000 from warrant exercises, raising total nominal share capital to DKK 78,957,151.50.
- Warrant Grants (Feb 6): 1,367,199 warrants granted to insiders with an exercise price of $0.073 per share (subject to exchange rate conversion and a floor of DKK 0.25).
- Remaining Warrant Authorization: Warrants to subscribe for an additional 36,478,961 ordinary shares remain available for future grant.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The primary material changes involve the company's capital structure and governance documents:
- Capitalization: Significant dilution occurred through the issuance of nearly 200 million new shares and the creation of new warrant pools.
- Articles of Association: Amended on January 31, February 5, and February 6, 2025, to reflect capital increases, new warrant terms, and reduced authorization for future warrant grants to investors and advisors (now capped at a nominal value of DKK 59,921,500).
- Warrant Exercise: Certain investor warrants were exercised on February 4, 2025, at the $2.71 price point.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard incorporation by reference. The document serves primarily as a notification of completed corporate actions and regulatory filings with the Danish Business Authority.
Key Facts for Investor Verification
- Verify the exact cash proceeds from the January 31 public offering and warrant exercises against the company's cash balance in subsequent filings.
- Confirm the dilution impact of the 199,868,050 new shares and the 1,367,199 new employee/director warrants on existing shareholders.
- Review the vesting schedules for the new warrants (1/36 per month for 1,167,199 warrants and 1/12 per month for 200,000 warrants) starting January 1, 2025.
- Monitor the remaining warrant authorization pool of 36,478,961 shares for potential future dilution.